Press Releases
Solidifies Standing as the First, Largest and Consistent Performing Issuer of PDP Oil & Gas Securitizations
BIRMINGHAM, AL / ACCESSWIRE / June 3, 2024 / Diversified Energy Company PLC (LSE: DEC)(NYSE: DEC) ("Diversified" or the "Company") is pleased to announce that on May 30, 2024, the Company closed on an asset backed securitization ("ABS") refinancing, creating the ABSVIII note (the "Transaction"). Diversified will use the proceeds from the Transaction to repay the... (continue reading...)
CALGARY, AB / ACCESSWIRE / June 3, 2024 / NXT Energy Solutions Inc. ("NXT" or the "Company") (TSX:SFD)(OTCQB: NSFDF) is pleased to announce it has issued convertible debentures (the "Debentures") to MCAPM LP for the principal amount of US$2,000,000, being approximately CDN$2,742,800, pursuant to the terms of a subscription agreement with NXT. The Toronto Stock Exchange (the "TSX") has provided conditional approval of the private placement. The Debentures bear interest... (continue reading...)
WILMINGTON, Del., June 03, 2024 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Nasdaq: PRLD), a clinical-stage precision oncology company, announced today that the Company will participate in two upcoming healthcare conferences in June.
Jefferies Global Healthcare Conference 2024:On Thursday, June 6th, at 1:30 p.m. ET, Kris Vaddi, Ph.D., Chief Executive Officer of Prelude will participate in a fireside chat. A live webcast of the fireside chat can be accessed... (continue reading...)
VANCOUVER, British Columbia, June 03, 2024 (GLOBE NEWSWIRE) -- Stallion Uranium Corp. (the "Company" or "Stallion") (TSX-V: STUD; OTCQB: STLNF; FSE: HM40) is pleased to announce that, further to its news release dated February 13, 2024, the Company has closed the purchase and sale agreement dated February 12, 2024 (the “Agreement”), under which the Company has sold Glorious Creation Limited (“Glorious”) 100% interest in its three Eastern Basin Projects,... (continue reading...)
DURHAM, N.C., June 03, 2024 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE), a leading global contract research organization (CRO), today announced that Chairman and Chief Executive Officer, Tom Pike and Chief Financial Officer, Jill McConnell will present at the Jefferies Global Healthcare Conference on Wednesday, June 5, 2024 at 11:00 am ET.
The live webcast will be available to investors and other interested parties by accessing the Fortrea Investor Relations... (continue reading...)
More Press Releases
View Older Stories-
RedHill Announces a New Patent Covering Opaganib in Combination with Immune Checkpoint Inhibitors, Valid Through 2040
-
Marriott International Announces Three Conversions to Bring Iconic Luxury Properties in the United States into the Marriott Bonvoy Portfolio Later This Summer
-
PawFury's Presale Raises Over $3 Million, Set To Surpass Pepe and SHIB
-
Coalesce Capital Announces Key Hires as Firm Continues to Expand Leadership Team
-
Dominion Energy Announces Closing of Sale of Western Natural Gas Distribution Assets Questar Gas, Wexpro
-
FibroGen to Present at Goldman Sachs 45th Annual Global Healthcare Conference
-
PEAK ROCK CAPITAL AFFILIATE COMPLETES PREVIOUSLY ANNOUNCED ACQUISITION OF HUFRIEDYGROUP
-
Calidi Biotherapeutics Presents CLD-101 Phase 1 Trial Update and Preclinical Data Highlighting RTNova and CLD-201 at 2024 ASCO Annual Meeting
-
Axsome Therapeutics Supports Alzheimer’s & Brain Awareness Month
-
At ASCO 2024, Treos Bio Reports Key Survival Results for Chemo-Free Regimen of PolyPEPI1018 Peptide Immunotherapy and Roche’s PD-L1 Inhibitor in Late-Stage Colorectal Cancer
-
ATHA Energy Commences 2024 Angilak Diamond Drilling Exploration Program
-
Recurrent Energy Announces Initial Closing of Investment from BlackRock
-
Xeris Presents New Post Hoc Analysis on Effects of Levoketoconazole (Recorlev®) in Cushing’s Syndrome Patients at ENDO 2024
-
Osisko Development to Complete Second Deferred Payment Installment in Connection With the Tintic Acquisition
-
Labcorp Announces New Strategic Service Offerings within Precision Oncology Portfolio
-
Grey Wolf Therapeutics Presents First Clinical Data for GRWD5769, a First-in-Class ERAP1 Inhibitor, at the 2024 American Society for Clinical Oncology (ASCO) Annual Meeting
-
Pulsenmore Appoints Len Farris as Chief Commercial Officer to Lead Global Expansion of Breakthrough Home Ultrasound Technology
-
Pershing Square Holdings, Ltd. Notes the Sale by Pershing Square Capital Management, L.P. of a 10% Common Equity Interest to Strategic Investors
-
Skye Bioscience to Present at Jefferies Global Healthcare Conference
-
StateServ Rebrands to Dragonfly Health
-
EagleRider Motorcycle Rental and Tours Announces New CEO Sebastian Schoepe
-
Enbridge Completes Acquisition of Questar Gas Company
-
Quince Therapeutics Receives U.S. FDA Fast Track Designation for EryDex System
-
Flow Beverage Corp. to Release Second Quarter 2024 Financial Results
-
Consor Holdings Announces Growth Investment from New Mountain Capital
-
Graphite One Announces Repricing of Stock Options
-
International Energy Forum Report Details EV Copper Hurdles
-
Dunes Point Capital, LP Announces Roofing Services Solutions' Acquisition of West Orange Roofing, LLC
-
Beyond Cancer Presents First-in-Class Clinical Data Showing an Immunogenic Response in Subjects with r/r Unresectable Solid Tumors Treated with Ultra-High Concentration Nitric Oxide (UNO)
-
Lithium Drilling Program Commences at East Vallée
-
Bruker Launches Transformative neofleX™ MALDI-TOF System for Spatial Biology Mass Spec Imaging (MSI) Applications
-
Gryphon Investors-Backed Thermal Technology Distribution Solutions Acquires Southwest Heater and Controls
-
Catona Climate to Offer High-Quality Carbon Credits through Integration with GreenLight Solution by Deloitte
-
Bausch + Lomb Launches Blink™ NutriTears® Clinically Proven Nutritional Supplement for Dry Eyes in the United States
-
Spruce Biosciences Presented Phase 2 POWER Study Results of Tildacerfont for the Treatment of Polycystic Ovary Syndrome at ENDO 2024
-
Andreas Nix is the new COO of the ZKW Group
-
TriSalus Life Sciences Highlights Clinical Data from Phase 1b PERIO-02 Trial, Studying Delivery of Nelitolimod via Pressure-Enabled Drug Delivery in Patients with Hepatocellular Carcinoma or Intrahepa
-
Ventra Health Appoints Erika Flowers as Chief People Officer
-
Alzheimer's Association Encourages Americans to Take Charge of Their Brain Health
-
IDRx Reports Updated Preliminary Phase 1 Data from Ongoing Phase 1/1b StrateGIST 1 Trial Supporting Best-in-Class Potential for IDRX-42 in Patients with GIST
-
redT Homes Honored as Best Individual Electric Only Builder Overall in 2023 Xcel ESNH Program
-
Rockwell Automation to Advance Intelligent Automation, Mobile Robotics in Manufacturing Logistics in Collaboration with NVIDIA
-
Aruna BIO Announces Appointment of Lynn Swann to its Board of Directors
-
Yellow Wood Partners Portfolio Company Suave Brands Company Completes ChapStick Acquisition
-
ModernFi Announces Integration with Q2's Digital Banking Platform
-
Pershing Square Capital Management, L.P. Announces Sale of 10% Common Equity Interest for $1.05 Billion to Strategic Investors
-
BPGbio Appoints Biopharma Industry Leader Scott Minick to Board of Directors
-
Alkermes Presents Data From Phase 1b Study of ALKS 2680 Demonstrating Improved Wakefulness in Patients With Narcolepsy Type 1 at SLEEP 2024
-
Turing Medical Launches New Brain Mapping and Targeting Solution at ASSFN Biannual Meeting
-
Dovenmuehle announces strategic business development promotions to support demand for its mortgage subservicing offerings